Liver Health & NASH

2 articles in Liver Health & NASH

NASH Fibrosis & Peptide Therapy

NASH Fibrosis Peptide Therapy Reversal

In March 2024, the FDA approved resmetirom for NASH, marking the first regulatory victory after two decades of failed Phase 3 trials—yet NASH fibrosis progression and peptide therapy's potential role in reversing scarring remain largely unexplored in clinical settings.

AdminUpdated Aug 119 min

Liver Health & NASH

Retatrutide NASH Liver Disease Research and Insights

Retatrutide NASH liver disease research is gaining momentum as scientists explore whether this weight loss peptide could also reverse liver damage in metabolic dysfunction-associated steatohepatitis (MASH), offering new hope for effective treatments.

AdminUpdated Jul 2813 min